Funding for this research was provided by:
Alberta Innovates - Health Solutions (10004299)
Text and Data Mining valid from 2018-06-18
Received: 21 January 2018
Accepted: 1 June 2018
First Online: 18 June 2018
Ethics approval and consent to participate
: The study was conducted at the Respiratory Clinical Trials Centre, University of Calgary, AB, Canada. All procedures were conducted in accordance with the standard operating procedures for the Respiratory Clinical Trials Centre. The study is registered with ExternalRef removed (ExternalRef removed). The study follows the Consolidated Standards of Reporting Trials (CONSORT) 2010 checklist (see Additional file InternalRef removed).This study was conducted in accordance with the Declaration of Helsinki. The Conjoint Health Research Ethics Board of the University of Calgary approved the study protocol, amendments, and consent form (REB14–1581). Written informed consent was obtained from all subjects.
: Not applicable.
: FHYG and JHD are founders, shareholders, management, and board members of SolAeroMed Inc., a biotechnology company with patent rights for S1226. GL, MF, AC, TYEM, CAP, and RL are shareholders in SolAeroMed Inc. VS, ER, GS, SG, and DEN have no conflicts of interest to declare.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.